ResultsIQ

ResultsIQ › Latest results › Rainbow Childrens Medicare Limited

Rainbow Childrens Medicare Limited Q4 FY25 results press release summary

NSE: RAINBOW · BSE: 543524

Results press release of 24 May 2025, summarised by AI from the filing.

Rainbow Children's Medicare Q4 FY25 revenue ₹3,701.1 mn (+8.5% YoY), PAT ₹565.5 mn (+10.7%), board recommends ₹3/share dividend.

Key takeaways

  1. Guidance No forward guidance provided; new hospitals expected to commence operations by Q1/Q2 FY26.
  2. Driver New beds commissioned over the past year integrated into the network; focus on improving occupancy.
  3. Risk EBITDA margin declined year-on-year in Q4 and FY25.

Original filing on BSE

Rainbow Childrens Medicare Limited Q1 FY27 results

As filed: Revenue ₹470 cr (+33% year on year), EBITDA ₹135 cr (+31% year on year), PAT ₹62.5 cr (+16% year on year), EBITDA margin 28.7% (−53 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹460 cr (+24% year on year), EBITDA ₹145 cr (+27% year on year), PAT ₹78.2 cr (+37% year on year), EBITDA margin 31.5% (+65 bps). Score 82 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 65 bps year on year. Tax rate 10%. Profit rose ₹21.2 cr on a year ago, more than the ₹6.0 cr it added the year before. Share price after the results: +2.2% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹445 cr (+12% year on year), EBITDA ₹147 cr (+10% year on year), PAT ₹73.9 cr (+7% year on year), EBITDA margin 33.0% (−67 bps). Score 47 of 100, In line with trend. Revenue, EBITDA and profit growth were in line with the company's own trend. EBITDA margin fell 67 bps year on year. Share price after the results: +0.1% in 30 days (Nifty 500: +0.4%).
  • Q2 FY26: Revenue ₹445 cr (+7% year on year), EBITDA ₹149 cr (+1% year on year), PAT ₹76.0 cr (−4% year on year), EBITDA margin 33.5% (−177 bps). Score 24 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin fell 177 bps year on year. Share price after the results: +2.1% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹353 cr (+7% year on year), EBITDA ₹103 cr (+11% year on year), PAT ₹54.0 cr (+35% year on year), EBITDA margin 29.2% (+100 bps). Score 49 of 100, In line with trend. Revenue growth was well below the company's own trend; EBITDA growth was in line with it; profit growth was well above it. EBITDA margin rose 100 bps year on year. Other income 28% of PBT. Revenue fell 5% from last quarter. Revenue rose ₹23.0 cr on a year ago, against ₹43.0 cr the year before. Share price after the results: −2.0% in 30 days (Nifty 500: +0.2%).
  • Q4 FY25: Revenue ₹370 cr (+9% year on year), EBITDA ₹114 cr (+9% year on year), PAT ₹57.0 cr (+12% year on year), EBITDA margin 30.8% (+2 bps). Score 44 of 100, In line with trend. Revenue and EBITDA growth were below the company's own trend; profit growth was above it. EBITDA margin was flat year on year. Revenue fell 7% from last quarter. Share price after the results: +8.7% in 30 days (Nifty 500: +1.0%).
  • Q3 FY25: Revenue ₹398 cr (+18% year on year), EBITDA ₹134 cr (+14% year on year), PAT ₹69.0 cr (+10% year on year), EBITDA margin 33.7% (−145 bps). Score 59 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 145 bps year on year. Revenue fell 5% from last quarter.
  • Q2 FY25: Revenue ₹417 cr (+25% year on year), EBITDA ₹147 cr (+26% year on year), PAT ₹79.0 cr (+25% year on year), EBITDA margin 35.3% (+12 bps). Score 70 of 100, Above trend. EBITDA margin rose 12 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Rainbow Childrens Medicare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.